Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: Health Ministry/PIB
From 130 maternal deaths per lakh live births during 2014–16, India has achieved a 43-point reduction in the Maternal Mortality Ratio (MMR) between 2022 and 2024, according to the government.
Currently, the MMR in the country stands at 87 maternal deaths per lakh live births.
In an official statement, the government credited the achievement to Pradhan Mantri Surakshit Matritva Abhiyaan (PMSMA), which today completed a decade.
Launched in June 2016, PMSMA provides free, comprehensive antenatal care to pregnant women at designated government health facilities on the 9th of every month.
More than 7.50 crore pregnant women have received antenatal services under PMSMA in addition to routine ANC check-up services in the last 10 years. The Extended PMSMA, launched in 2022, strengthens follow-up care and tracking for high-risk pregnancies.
"Over the past decade, the Pradhan Mantri Surakshit Matritva Abhiyaan has transformed the delivery of antenatal care in India. Quality maternal healthcare is now more accessible, systematic and responsive," the statement said.
“The remarkable decline in the Maternal Mortality Ratio from 130 to 87 over the past decade demonstrates how focused interventions can save thousands of lives,” it added.
The government noted that PMSMA works through:
"PMSMA has demonstrated that when quality healthcare reaches women at the right time, it saves lives, prevents complications and creates healthier beginnings for families and future generations," the govt said.

The PMSMA service package includes clinical examinations, laboratory investigations (blood and urine tests), ultrasonography, medicines, and counselling on nutrition, birth planning, and safe pregnancy practices.
Key features include:
The program is available to:

MMR is defined as the number of maternal deaths per one lakh live births during a given period.
A maternal death refers to the death of a woman during pregnancy or within 42 days of termination of pregnancy due to causes related to or aggravated by the pregnancy or its management, excluding accidental or incidental causes.
Maternal health remains one of the clearest indicators of the strength and inclusiveness of a country's healthcare system.
"As India marches towards Viksit Bharat@2047, PMSMA will continue to transform the maternal healthcare landscape by ensuring that every pregnancy is safer and every mother receives the care she deserves. With continued commitment and collective action, PMSMA can help usher in an era where no woman loses her life while giving life, strengthening the foundations of a healthier and more prosperous India," the statement said.
Credit: iStock
Health officials in Kerala have reported two deaths caused by West Nile fever in Ernakulam district.
The deceased was identified as Muraleedharan, a 70-year-old man from Kadangalloor near Aluva. The elderly man died while undergoing treatment on Monday at Kalamassery Medical College, officials said.
Muraleedharan, who was suffering from cancer and had respiratory problems, was admitted to the Medical College Hospital a few days ago with symptoms of West Nile fever. This is the second death from West Nile fever in the Ernakulam district in a week.
Saraswathiyamma, a native of Paravur, died of West Nile fever the other day. Many people have reportedly sought treatment at various hospitals in Ernakulam district with West Nile fever and dengue fever symptoms.
Following the incident, the state health department urged people to remain cautious and also issued an advisory urging the public to take precautions against the mosquito-borne disease.
The West Nile Fever "is caused by a flavivirus commonly found in migratory birds and is transmitted to humans through the bite of infected mosquitoes," the department said, in a statement.
It clarified that "the disease does not spread from person to person and that preventing mosquito bites is the most effective way to avoid infection".
According to health authorities, symptoms may include fever, high body temperature, stiffness of the neck, behavioral changes, confusion, semi-consciousness, or loss of consciousness, PTI reported.
The statement warned that severe infection could affect the nervous system and lead to conditions such as encephalitis and meningitis.
"Elderly persons, those with low immunity, individuals with underlying illnesses, pregnant women, and children have been identified as high-risk groups requiring special attention. Culex mosquitoes, which breed in stagnant and polluted water bodies, drainage channels, septic tanks, marshy areas, paddy fields, and overgrown vegetation, are the primary carriers of the disease," the statement said.
The disease is spread through mosquito bites, and most who get infected do not have any symptoms. However, one in every five infected people has a fever, headache, body aches, and other flu-like symptoms.
The West Nile virus also infects the nervous system and is capable of causing serious brain or spinal cord inflammation.
According to the WHO, West Nile Virus is a member of the flavivirus genus and belongs to the Japanese encephalitis antigenic complex of the family Flaviviridae.
The mosquitoes become infected when they feed on birds that carry the virus in their blood, and then bite humans and infect them.
The symptoms include fever, headache, muscle aches, nausea and vomiting, diarrhoea, rash around the chest and back, swollen lymph nodes, sore throats, and pain behind the eyes.
In severe cases, individuals may have an intense headache, high fever, stiff neck, making you unable to move your chin towards your chest, confusion, muscle weakness, loss of control over your muscle movements, seizures, paralysis, and coma.
While the mosquitoes that feed on infected birds are the carriers, there is still a lack of evidence to determine whether it comes directly from the birds. The incubation period for symptoms to show up is two to six days, but it can extend to 14 days, too.
It can be transmitted from a pregnant person to their fetus, through human milk, blood transfusion, and organ transplant. People who are over the age of 60, have cancer, diabetes, or high blood pressure are more prone to the virus.
There are no treatments or antiviral medications available for it. However, one can treat the mild symptoms at home with over-the-counter medications that you take for a cold or the flu. The best way to prevent is to protect yourself from mosquito bites.
Credit: Washington University
Dr. Ravi Vij, an Indian-origin cancer specialist and an alumnus of Maulana Azad Medical College in New Delhi, has been given the prestigious honor of a professorship for his contributions to advancing treatments for blood cancers.
He has been appointed as the inaugural Jeffrey S. and Prue H. Gershman Distinguished Professor in the John T. Milliken Department of Medicine at Washington University School of Medicine.
Vij is currently a professor of medicine in the department’s Division of Oncology. The professorship has been funded by St. Louis philanthropists Jeffrey and Prue Gershman, who support local education, health, and arts organizations.
In a statement, Chancellor Andrew D. Martin stated that this professorship, "will accelerate progress against blood cancers by supporting Dr. Vij’s work to bring new, more effective treatments to patients".
Martin also lauded Dr. Vij’s leadership, noting that it has "helped grow WashU Medicine’s reputation as a national force in stem cell transplantation and immunotherapy".
Leading Blood Cancer Research
Dr Vij's work includes studying the genetic underpinnings and cellular microenvironment of multiple myeloma — a cancer of the plasma cells in bone marrow.
He also treats patients at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, and is the principal investigator of the Multiple Myeloma Tissue Banking initiative at Siteman.
He has led several clinical trials of investigational therapies for blood cancers, including immunotherapy agents and novel stem cell transplant strategies, that later became standard treatments. He has authored more than 300 scientific publications in the field of blood cancers.
Also read:I’m Cancer-Free After 14 Years, Says Robin Quivers
Contributions Beyond Research
Beyond his research into blood cancer, Dr. Vij has served on the American Society of Clinical Oncology education and scientific committees and on the myeloma committees of the Clinical Trials Network and Alliance for Clinical Trials in Oncology.
He currently serves as senior editor of the journal Clinical Lymphoma, Myeloma and Leukemia and is a past chair of the American Society of Hematology scientific committee on plasma cell dyscrasias, a group of disorders linked to blood cancers.
His accolades include the Multiple Myeloma Research Foundation Innovator Award, the Center of Excellence Award, and the Leukemia & Lymphoma Society Visionary of the Year Award.
A respected educator, Vij has mentored 25 early-career researchers and received the Teacher of the Year Award from the Hematology and Oncology Fellowship Program at WashU Medicine in 2007.
Dr. Vij completed his medical education at Maulana Azad Medical College in New Delhi, India, followed by postgraduate training at Halifax General Hospital and Royal Infirmary in the United Kingdom.
He completed an internal medicine residency at Rush University in Chicago and fellowships in medical oncology, hematology, and bone marrow transplantation at WashU Medicine. He joined the WashU Medicine faculty in 2000.
What Is Blood Cancer?
Blood cancer is broadly classified into three main types: leukemia, lymphoma, and myeloma. Leukemia is a cancer of the blood and bone marrow, while lymphoma affects the lymphatic system, particularly the lymph nodes and immune cells. Myeloma is a cancer of plasma cells found in the bone marrow.
These cancers disrupt normal blood cell function and can cause symptoms such as fatigue, infections, and unexplained bleeding.
Symptoms And Treatment
Common symptoms of blood cancer include:
The causes and risk factors for blood cancer vary. Genetic mutations, exposure to radiation or harmful chemicals, certain infections, and a family history of blood cancer are known risk factors. The risk of developing blood cancer generally increases with age.
Advanced treatment options for blood cancers include immunotherapies such as CAR-T cell therapy and stem cell transplantation.
© 2024 Bennett, Coleman & Company Limited